Enzo Biochem Inc

Enzo Biochem — Proxy Contest (January 2020)

21 slides from Enzo Biochem's proxy contest presentation, Jan 13, 2020

  1. Slide 1: Refuting Enzo's False and Misleading Claims

    oon mlhimilti Harbert Management Corporation Refuting Enzo’s False and Misleading Claims January 10, 2020

  2. Slide 2: Important Information

    Important Information This presentation, the materials contained herein, and the views expressed herein (this Presentation") are for discussion and general informational purpases only. This Presentation does not have regard to the specific investment objective, financial situation, suitabilty, or th

  3. Slide 3: Enzo's investor presentation is an exercise in obfuscation

    Enzo’s recent investor presentation is an exercise in obfuscation - it is rife with misleading claims and continues to demonstrate the Company's aversion to reality. Enzo repeatedly attempts to distract investors by attacking Harbert - when this is really about why fresh, independent voices with exc

  4. Slide 4: Stale Promises Ring Hollow

    Enzo’s Stale Promises Ring Hollow 2015 Enzo Investor Presentation 2020 Enzo Investor Presentation EXECUTIVE SUMMAR} fi Fn | Y Executing on a corporate strategy which has positioned the company | | tothrive in the challenging MDx marketplace fl ¢ The value of Enzo is beginning to be appreciated by th

  5. Slide 5: Shareholders Have Heard this Story Before

    Shareholders Have Heard this Story Before @Enzo's Market Opportunity Is Substantial By continuing to execute its three-pronged strategy for value creation, Enzo is poised to capitalize ‘on significant market opportunity aos oppo n maleeua dag cst i sgnifean, th ‘Infectious Diseases, 150 $3,300 @0ch

  6. Slide 6: "Legacy of Groundbreaking Innovation" Has Not Created Value

    Enzo’s “Legacy of Groundbreaking Innovation’ Has Not Created Value = “= ... This is clearly nottrue. | je aio‘ @Enzo Has a Legacy of Groundbreaking a 4.972% 1 612% 1.251% Innovation Total Shareholder Return* Enzo's track record of industry disruption and strategic reinvention positions us tor aca Sh

  7. Slide 7: Shareholders are Still Waiting

    holders are Still Waiting Executing Three-Pronged Strategy for Value | Enzo claimed it would announce a strategic Creation I relationship by the end of calendar 2019. Yet Enzo is making meaningful progress in executing its three-pronged strategy designed to | all investors have are more unmet promis

  8. Slide 8: "Meaningful Progress" — Let's Look at the Numbers

    Enzo’s “Meaningful Progress” — Let's Look at the Numbers $110 $105 $100 $95 $90 $85 sa i $15 | | a Q22018 Q32018 Q4 2018 12019 Q2 2019 32019 42019 Q1 2020 |LTM Revenue by Quarter + fc etrey iba uenrotl tay Eo sew ase "aa ae rerio a ey nssnanseto ey + Anse comes neon cts dogo ne bs oer set nt pe + mg

  9. Slide 9: "Understanding" Enzo's Business

    “Understanding” Enzo’s Business 2015 Enzo Investor Presentation 2020 Enzo Investor Presentation c tory by an investor that 7 ra admitted he “doesn’t understand our business’) During our engagement it was immensely I clear that Lone Starhas absolutely | } nothing of value to offer the Company and | I

  10. Slide 10: Inaccurate Representation of Its "Licensing Strategy"

    Enzo’s Inaccurate Representation of Its “Licensing Strategy’ “= On slide 29 of Enzo’s 2020 investor | —_ 7 | Enzo's timeline here is I presentation, it compares legal settlements to | | @ Pa Eta ear Tis dated oP i rea eT ws R&D spend. Then, on slide 51, Enzo sera ies ae Spending:on: Red) andlega | c

  11. Slide 11: Cost Savings: Reading the Fine Print

    Cost Savings: Reading the Fine Print 2015 Enzo Investor Presentation 2020 Enzo Investor Presentation 10% SAVINGS TO MARKET HOW ENZO CAN DELIVER SIGNIFICANT SAVINGS TOTS CUSTOMERS 0 Enzo’s Unique Novel Diagnostics Model Is Average Gross Margin of nical Services Companies"? “30% Comprehensive and Deli

  12. Slide 12: Misaligned Compensation Structure

    Enzo’s Misaligned Compensation Structure Financial Performance Measures—Revenue Corporate Revenses—trade and service Payout—Revenue Financial Performance Meacure>—Proft & Adjusted EBITDA Corporate operating loss improvement $23 djusted EBITDA improvement Payout—Profits & Adjusted EBITDA 80% Harbert

  13. Slide 13: Enzo Has Only Improved Governance Under Investor Pressure

    Enzo Has Only Improved Governance Under Investor Pressure Reactive eee Po { According to SEC ‘lings, Enzo has only mentioned Board \ | “refreshment” when under activist pressure. I Harbert Claim: Enzo's governance benefit insiders at the expense of other stakeholders 1. 12/22/15 Open Letter to Share

  14. Slide 14: Enzo Should Check its Facts

    Enzo Should Check its Facts Ll le ell | | Our every attempt to engage in meaningful | | and constructive dialogue to bring change | What Is Harbert Hiding? to Enzo's Board was met with ; ; ; , unproductive and discouraging responses We believe Harbert's disingenuous behavior and lack of healthcare e

  15. Slide 15: Directors

    Enzo’s Directors | Elazar Rabbani I Ly! Dr Eeuoe Heme _ 7 x 10 year cumulative I Ly Enzois only public I TSR : 49% I company experience | x Entrenched i | « Cumulative TSR over x Compensated for I | _ tenure: -63% ! value destruction I ee ae ee eee | Dov Perlysky I , nea amd . ud x 5year cumulative

  16. Slide 16: Seeing Through Enzo's Engagement Facade

    Seeing Through Enzo’s Engagement Facade 1. 2 Enzo repeatedly seeks to paint Harbert as “unconstructive’ and criticize our engagement process — claiming in its presentation to “have no basis for evaluating” our nominees and recently telling Harbert the Company “knows nothing about our candidates.” *

  17. Slide 17: Fabian Blank: The Right Fit for Enzo's Board

    Fabian Blank: The Right Fit for Enzo’s Board aan: [ 44% of Life Sciences Products Revenue is outside of \ Harbert Nominee: Fabian Blank / | U.S., making Mr. Blank’s global experience extremely l I l l | Fabian Blank’s hyper-regional and i irrelevant experience is is not additive to Enzo's Board I va

  18. Slide 18: Peter Clemens: The Right Fit for Enzo's Board

    Peter Clemens: The Right Fit for Enzo’s Board Harbert Nominee: Peter Clemens, IV Peter Clemens leaves behind a trail of litigation from his prior roles and has no public company directorship experience eclosedin resume (our sole basis for evaluating him) isnot relevant to Enzo } Named de'endartin fi

  19. Slide 19: Attempts to Distract Shareholders

    Enzo’s Attempts to Distract Sha Further, the “experience” of Enzo’s incumbent nominees have resulted i in total shareholder returns % over the past three years. Harbert's Inexperience in Healthcare Is Troubling ite not eurprising that Harbert admitted to not understanding the laboratory business, ci

  20. Slide 20: Harbert's Healthcare Investment Experience

    Harbert’s Healthcare Investment Experience wellcentive @anutRA yi! MaxCyte INIPACE (surgical WO RPL Eo Wie pice ONVerd anoval (~ AxoGen. as . FA CAD) BP \\ Health Mal gléo | cx Q) tate

  21. Slide 21: Contact Information

    Contact Information Shareholders If you have any questions, or need assistance voting your BLUE proxy card, please contact: PARTNERS 1212 Avenue of the Americas, 24th Floor New York, NY 10036 Telephone for Banks, Brokers, and International Shareholders: +1 212-297-0720 Shareholders may call toll-fre

Enzo Biochem — Proxy Contest (January 2020) on 6ix